July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
The Relationship Between Cilio-retinal Arteries and Advanced Age-related Macular Degeneration in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Author Affiliations & Notes
  • Clay Bavinger
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania, United States
  • Gui-Shuang Ying
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania, United States
  • Ebenezer Daniel
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania, United States
  • Maureen G Maguire
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Clay Bavinger, None; Gui-Shuang Ying, None; Ebenezer Daniel, None; Maureen Maguire, Genentech/Roche (C)
  • Footnotes
    Support  U10 EY017823, U10 EY017825, U10 EY017826, and U10 EY017828
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1181. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Clay Bavinger, Gui-Shuang Ying, Ebenezer Daniel, Maureen G Maguire; The Relationship Between Cilio-retinal Arteries and Advanced Age-related Macular Degeneration in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Invest. Ophthalmol. Vis. Sci. 2019;60(9):1181.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : A recent report revealed that cilio-retinal arteries (CRA) may confer a protective effect against developing advanced age-related macular degeneration (AMD). We sought to further characterize the relationship between the presence of CRA and incidence of advanced AMD, including geographic atrophy (GA) and choroidal neovascularization (CNV).

Methods : CATT participants with CNV in the study eye and without advanced AMD in the fellow eye at baseline and who were followed-up for 5 years were eligible for this analysis. Presence of CRA in both eyes was determined by 2 graders, masked to all clinical data, using color and red-free fundus photographs and fluorescein angiography. Presence of advanced AMD through 5 years of follow-up had previously been determined in the CATT study. Among fellow eyes, we assessed the association of CRA with incidence of a CNV and GA at 5 years. Similar analysis was performed among study eyes for association between CRA and incidence of GA. In addition, we compared the proportion with CRA between the study eye with CNV and fellow eye without CNV at baseline.

Results : 700 eyes from 350 subjects were included. The mean age was 77 years and 34% were men. CRA was present in 19.4% of fellow eyes and 20.9% of study eyes (p=0.60). CRA in fellow eyes was not associated with incidence of CNV at 5 years (45.0% in eyes without CRA, and in 44.8% of eyes with CRA, p=0.99), nor with incidence of GA at 5 years (40.0% of eyes without CRA, and 37.9% of eyes with CRA, p=0.89, Table 1). CRA in study eyes treated with anti-VEGF agents was not associated with incidence of GA at 5 years (39.0% in study eyes without CRA and 36.6% in eyes with CRA, p=0.72). In addition, there was no association between presence of CRA and AREDS severity score at baseline (p=0.82).

Conclusions : Contrary to previous publications, our analysis did not found any association between CRA and incidence of CNV and GA. The reason for the conflicting results is unclear but may be partly explained by the difference in study populations; the study eyes in CATT had CNV at baseline, whereas previous publications used data from cohorts with less advanced AMD.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

Table 1: Association of baseline CRA with baseline AREDS scale, and incidence of CNV and GA in fellow eye, and baseline CRA in study eye with incidence of GA in study eye in 5-Year cohort

Table 1: Association of baseline CRA with baseline AREDS scale, and incidence of CNV and GA in fellow eye, and baseline CRA in study eye with incidence of GA in study eye in 5-Year cohort

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×